GSK Investigational Site

Madison, Wisconsin 53972

1 studies enrolling now · 87 studies all time

What they study most

Activity/Exercise Induced Bronchospasm, Acute Coronary Syndrome, Asthma, Autoimmune Diseases, Bronchospasm, Cancer, Crohn's Disease, Cystic Fibrosis, Depressive Disorder, Depressive Disorder, Major, Diabetes Mellitus, Diabetes Mellitus, Type 2

Studies at this site

• A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) — Recruiting now
• Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM — Running, not enrolling
• Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM — Running, not enrolling
• Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) — Running, not enrolling
• Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma — Running, not enrolling
• A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer — Running, not enrolling
• A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) — Running, not enrolling
• A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody — Completed
• Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) — Completed
• Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer — Stopped early
• GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer — Stopped early
• An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures — Stopped early
• Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure — Completed
• Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) — Completed
• Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma — Completed
• Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children — Completed
• Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age — Completed
• Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome) — Completed
• Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus — Completed
• A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise — Completed
• Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age — Completed
• A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. — Completed
• 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old — Completed
• Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer — Completed
• Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants — Completed
• Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans. — Completed
• An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease — Stopped early
• Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma — Completed
• Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration — Completed
• Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer — Completed
• Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma — Completed
• Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide — Completed
• 28 Day Repeat Dose in Cystic Fibrosis Patients — Completed
• A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder — Completed
• Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS) — Completed
• LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures — Completed
• Seasonal Affective Depression (SAD) Study — Completed
• Open-Label Extension Study of GSK1605786A — Stopped early
• GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease — Stopped early
• Study of GSK1363089 in Metastatic Gastric Cancer — Completed
• The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial — Completed
• GSK706769 Repeat Dose Study — Completed
• Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome — Stopped early
• Phase 0 Microdose Study — Completed
• The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) — Completed
• Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age — Completed
• Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug — Completed
• Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate — Completed
• GSK1349572 Repeat Dose Escalation and Relative Bioavailability Study — Completed